Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein

References

• Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342:836–43.
   PubMed Web of Science ®Google Scholar
• Weinhold B, Ruther U. Interleukin-6-dependent and -independent regulation of the human C-reactive protein gene. Biochem J. 1997;327:425–9.
   PubMed Web of Science ®Google Scholar
• Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis. 1999;145:375–9.
   PubMed Web of Science ®Google Scholar
• Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, Eckel RH. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation. 2002;106:1447–52.
   PubMed Web of Science ®Google Scholar
• Strandberg TE, Vanhanen H, Tikkanen MJ. Associations between change in C-reactive protein and serum lipids during statin treatment. Ann Med. 2000;32:579–83.
   PubMed Web of Science ®Google Scholar
• Berthold HK, Naini A, Di Mauro S, Hallikainen M, Gylling H, Krone W, Gouni-Berthold I. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf. 2006;29:703–12.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Ballantyne CM, Veltri E, Shah A, Bird S, Lin J, . Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol. 2009;103:369–74.
   PubMed Web of Science ®Google Scholar
• Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J. 2010;31: 1633–9.
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I, Berthold HK, Gylling H, Hallikainen M, Giannakidou E, Stier S, . Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis. 2008;198: 198–207.
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I, Berthold HK, Chamberland JP, Krone W, Mantzoros CS. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol (Oxf). 2008;68:536–41.
   PubMed Web of Science ®Google Scholar
• Krysiak R, Okopien B. The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. J Cardiovasc Pharmacol. 2011;57:505–12.
   PubMed Web of Science ®Google Scholar
• Devaraj S, Chan E, Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab. 2006;91: 4489–96.
   PubMed Web of Science ®Google Scholar
• Lee SH, Kang SM, Park S, Jang Y, Chung N, Choi D. The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A2. Clin Cardiol. 2011;34:108–12.
   PubMed Web of Science ®Google Scholar
• Undas A, Machnik A, Potaczek DP, Wypasek E, Zmudka K, Tracz W. Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events. J Cardiovasc Pharmacol. 2011;58: 167–72.
   PubMed Web of Science ®Google Scholar
• Hoppe C, Kuypers F, Larkin S, Hagar W, Vichinsky E, Styles L. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol. 2011;153:655–63.
   PubMed Web of Science ®Google Scholar
• Kater AL, Batista MC, Ferreira SR. Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjects. Diabetol Metab Syndr. 2010;2:34.
   PubMed Web of Science ®Google Scholar
• Nozue T, Michishita I, Mizuguchi I. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. J Atheroscler Thromb. 2010;17:37–44.
   PubMed Web of Science ®Google Scholar
• Yagi S, Akaike M, Aihara K, Iwase T, Ishikawa K, Yoshida S, . Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J Atheroscler Thromb. 2010;17:173–80.
   Google Scholar
• Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ, . Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?J Am Coll Cardiol. 2007;49:1035–42.
   PubMed Web of Science ®Google Scholar
• Rudofsky G, Reismann P, Groener JB, Djuric Z, Fleming T, Metzner C, . Identical LDL-cholesterol lowering but non-identical effects on NF-kappaB activity: high dose simvastatin vs combination therapy with ezetimibe. Atherosclerosis. 2012;223:190–6.
   PubMed Web of Science ®Google Scholar
• Berneis K, Rizzo M, Evans J, Rini GB, Spinas GA, Goedecke JH. Interleukin-18 levels are associated with low-density lipoproteins size. Eur J Clin Invest. 2010;40:54–5.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, . Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409–15.
   PubMed Web of Science ®Google Scholar
• Pesaro AE, Serrano CV Jr., Fernandes JL, Cavalcanti AB, Campos AH, Martins HS, . Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin. Int J Cardiol. 2011;158:400–404.
   PubMed Web of Science ®Google Scholar
• Dawson JA, Choke E, Loftus IM, Cockerill GW, Thompson MM. A randomised placebo-controlled double-blind trial to evaluate lipid-lowering pharmacotherapy on proteolysis and inflammation in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2011;41:28–35.
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–40.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group, Jonathan E, Derrick B, Emma L, Sarah P, John D., Jane A, Rory C. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet. 2011;377:469–76.
   PubMed Web of Science ®Google Scholar
• Wijnstok NJ, Twisk JW, Young IS, Woodside JV, McFarlane C, McEneny J, . Inflammation markers are associated with cardiovascular diseases risk in adolescents: the Young Hearts project 2000. J Adolesc Health. 2010;47:346–51.
   PubMed Web of Science ®Google Scholar
• Seedorf U, Engel T, Lueken A, Bode G, Lorkowski S, Assmann G. Cholesterol absorption inhibitor Ezetimibe blocks uptake of oxidized LDL in human macrophages. Biochem Biophys Res Commun. 2004;320:1337–41.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr., Kastelein JJ, . Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175–82.
   PubMed Web of Science ®Google Scholar